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The International Pediatric 
Peritonitis Registry: Starting to 
walk
I Teitelbaum1
The International Pediatric Peritonitis Registry (IPPR) was created to 
assess and evaluate the validity of the pediatric peritonitis treatment 
guidelines issued by the International Society for Peritoneal Dialysis. 
The study by Schaefer et al., one of the first to emerge from the 
IPPR, describes regional variability in the frequency of culture-
negative peritonitis and of Gram-negative infections. This analysis 
is a crucial step in the development of evidence-based treatment 
recommendations whereby to improve outcomes for the youngest 
peritoneal dialysis patients.
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The degree of utilization of peritoneal 
dialysis as renal replacement therapy in 
adults varies widely around the globe, 
ranging from as high as 40%–70% in 
New Zealand and Mexico to as low 
as 8% or less in the United States and 
Japan.1 In contrast, the utilization of 
peritoneal dialysis in pediatric patients 
is approximately 50% worldwide.2 This 
is due largely to improved quality of 
life, the ability to maintain attendance 
in school, and the ability to avoid place-
ment of percutaneous vascular access in 
small patients in whom ﬁstulae or grafts 
cannot be established. For both patient 
groups, however, infectious complica-
tions, particularly peritonitis, remain 
a major cause of peritoneal membrane 
failure and patient transfer to hemodi-
alysis (Figure 1).3 This is especially true 
of the pediatric population, in which the 
frequency of peritonitis is even greater 
than that in adults.4
The microbiologic pattern of peri-
toneal dialysis-related peritonitis in 
adults has been carefully defined in 
various parts of the world, including 
North America, Europe, Asia, and Aus-
tralia. Although there is some regional 
variability, Gram-positive organisms 
are most commonly implicated, gen-
erally accounting for 50%–65% of 
episodes; 15%–25% are due to Gram-
negative organisms, 10%–20% are 
culture-negative, and fewer than 5% are 
accounted for by fungi and mycobacte-
ria. Knowledge of this microbiologic 
pattern has enabled the International 
Society for Peritoneal Dialysis (ISPD) 
to issue informed recommendations for 
the empiric treatment of peritonitis and 
for the subsequent modiﬁcations of the 
antibiotic regimen once the organism 
has been identiﬁed. These recommen-
dations have been periodically updated 
as newer information regarding antimi-
crobial susceptibilities and other best-
practice patterns has become available; 
the most recent of these was published 
in 2005.5
In 2000 the ISPD published its ﬁrst 
set of peritonitis treatment guide-
lines designed to speciﬁcally address 
the needs of pediatric patients.6 These 
guidelines were largely opinion-based, 
as the efficacy of specific treatment 
algorithms in pediatric patients had 
never been evaluated. Furthermore, in 
contrast to adults, the microbiology of 
peritoneal dialysis-related peritonitis 
around the globe had not been deﬁned 
in the pediatric population. The Inter-
national Pediatric Peritonitis Registry 
(IPPR) was created in 2001 with the 
objective of critically assessing and eval-
uating the validity of the 2000 pediatric 
peritonitis treatment guidelines.7 An 
overall analysis of data from the IPPR 
to date — including the clinical features 
of peritonitis at presentation, antibiotic 
sensitivities, the extent of responsive-
ness to empiric treatment, and sugges-
tions for modiﬁcation of the empiric 
treatment recommendations — is being 
published elsewhere.8 Schaefer et al.9 
(this issue) report on other important 
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aspects of data obtained from the IPPR: 
variations in the clinical presentations 
of peritonitis as well as in the microbio-
logic causes thereof and antibiotic sus-
ceptibilities around the globe.
Before undertaking an analysis of this 
study, it is important to recognize at the 
outset what the IPPR was not designed 
to do: it was not designed to track the 
total number of peritoneal dialysis 
treatment days for each patient at every 
unit in each region. Therefore, lacking a 
denominator, the absolute rates of peri-
tonitis incidence within each region 
(that is, one episode per x patient-
months) could not be calculated. These 
would certainly have been of interest; of 
greater importance, however, is the need 
— as stressed in the 2005 ISPD recom-
mendations — for each peritoneal dialy-
sis program or unit to carefully monitor 
its individual infection rates in an ongo-
ing fashion as part of a continuous qual-
ity-improvement program.5 The ISPD 
suggests that one peritonitis episode per 
18 patient-months should be considered 
the maximum acceptable rate; this may 
be more diﬃcult to accomplish in pedi-
atric populations, especially those with 
a large proportion of infants or very 
young children. The IPPR investigators 
encountered an average of 1.4 episodes 
of peritonitis per patient in a period 
of 38 months. Knowledge of the mean 
duration of peritoneal dialysis in those 
patients who contracted peritonitis 
during the specified time interval 
would have allowed for calculation of 
a ‘worst-case’ incidence rate; however, 
this information was not provided.
The lack of absolute infection rates 
notwithstanding, the study by Schaefer 
et al.9 nevertheless provides very valu-
able information regarding global 
variations in patterns of disease presen-
tation, causative microbiologic agents, 
and antibiotic susceptibilities. Most 
prominent among these is the striking 
variability in the frequency of culture-
negative peritonitis. No more than 20% 
of all peritonitis episodes should be cul-
ture-negative;5 yet this rate was greatly 
exceeded in several regions of the globe, 
including Asia, Mexico, and Turkey. The 
authors state that they found no system-
atic diﬀerences in culture techniques to 
account for these diﬀerences. The ideal 
culture technique, which yields a cul-
ture-negative rate less than 5%, requires 
centrifugation of a 50 cc aliquot of the 
peritoneal ﬂuid followed by re-suspen-
sion of the pellet in no more than 5 cc 
of saline and culture in both solid and 
liquid media.5 This cannot always be 
accomplished in hospital-based dialy-
sis units and may be totally impractical 
in small and/or remotely located units. 
Alternatively, 5–10 cc of peritoneal 
eﬄuent may be directly inoculated into 
blood-culture bottles. This would obvi-
ate the concern regarding long transport 
times before culture and, with proper 
attention to avoiding extremely cold 
temperatures, should yield a culture-
negative rate under 20%. Units lacking 
centrifugation capability should keep a 
supply of blood-culture bottles on hand 
for this purpose.
Also of note is the very high frequency 
of Gram-negative infections, especially 
those with Pseudomonas species, in 
some regions of the globe, including the 
United States and Argentina. The obser-
vation that this correlates with greater 
use of topical exit-site care may seem 
counterintuitive at first. However, as 
Schaefer et al.9 point out, use of mupi-
rocin or other agents without activity 
against Gram-negative organisms may 
have resulted in preferential coloniza-
tion of the exit site with mupirocin-
resistant organisms.
Bernardini et al. have recently dem-
onstrated in adults that daily use of 
gentamicin cream at the exit site is 
associated with a 57% decrease in the 
frequency of exit-site infections and a 
35% decrease in the frequency of peri-
tonitis as compared with use of mupi-
rocin.10 The decrease in Gram-negative 
peritonitis was even more striking, and 
peritonitis due to Pseudomonas species 
was eliminated. The use of gentamicin 
rather than mupirocin for routine exit-
site care should be studied — or perhaps 
adopted empirically — in the pediatric 
population as well.
It is also interesting to speculate 
regarding a possible relationship 
between the frequency of Gram-nega-
tive infections and other demographic 
and epidemiologic factors. Although 
Gram-negative infections are com-
monly of bowel origin, there is evidence 
for a role for touch contamination and/
or exit-site infection as well.5,10 The 
frequency with which double-cuffed 
catheters were used in the study popu-
lation was lowest in the United States. 
Does the absence of the second (super-
ﬁcial) cuﬀ, resulting in elimination of 
a significant barrier to pericatheter 
migration of bacteria, explain the high 
frequency of Gram-negative peritonitis 
in the United States? Furthermore, the 
prevalence of infants below age 2 years 
was highest in the United States. Does 
the high prevalence of infants, with the 
potential for touch contamination from 
soiled diapers, further exacerbate this 
problem (though it must be acknowl-







Figure 1 | Reasons for transfer of pediatric patients out of peritoneal dialysis (%). (Adapted 
from ref. 11.)
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highest overall Gram-negative infection 
rate — had no infants below age 2 in the 
study population)?
Finally, it is of interest that the assign-
ment of empiric antibiotic therapy by 
perceived risk stratiﬁcation had no eﬀect 
on eventual patient outcomes. This will 
undoubtedly be reﬂected in the next set 
of pediatric guidelines by a uniform set of 
recommendations, likely to parallel those 
in adults. Each individual unit should 
then use those guidelines, coupled with 
knowledge of its own patterns of causa-
tive organisms and antibiotic susceptibili-
ties, to devise the most suitable treatment 
algorithms for its particular patient popu-
lation. The clinicians responsible for the 
IPPR are to be applauded for launching 
this important continuous quality-
improvement program. By careful data 
collection and analysis, they have enabled 
the promulgation of evidence-based 
treatment recommendations whereby to 
improve outcomes for the youngest peri-
toneal dialysis patients.
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